Abstract
A new oral contraceptive (OC) containing dienogest (DNG) as progestagen with both antiandrogenic and antimineralocorticoid activity has been developed. Our objective was to compare the effects of 35 μg ethinil-estradiol (EE)/2 mg cyproterone acetate (CPA), 30 μg EE/150 μg desogestrel (DSG) and 30 μg EE/2 mg dienogest (DNG) on mild to moderate cases of acne. This prospective, comparative study was completed over 9 treatment cycles. A total of 114 young women with facial acne and seborrhea were recruited. Treatment was assigned in three groups: OC containing CPA or DSG for 6–9 cycles in 96 cases and DNG for 6 cycles in 18 cases. Acne lesions and sebum production were evaluated. After 3 cycles, all cases showed improvement of skin appearance. Depending on cases' evolution, we prolonged treatment for 6 cycles in 91 cases and for 9 cycles in other 23. At the end of the therapy, in first two groups, we obtained complete remission of acne in 92%, of seborrhea in 78%, of inflammatory lesions in 73%. In those 18 cases receiving OC containing DNG, we remarked superior results: improvement of lesions after 1-month treatment and complete healing after 6 cycles. This new preparation EE/DNG may provide useful hormone therapy for adolescents with androgen-related conditions such as greasy skin and acne.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call